MMID

Itron Signs Contract to Transform Water Operations in Indonesia’s Fully Integrated Industrial Estate

Retrieved on: 
Tuesday, March 7, 2023
Environment, Technology, Utilities, Alternative Energy, Green Technology, Energy, Other Natural Resources, Data Management, Natural Resources, City, MMID, Outcome, PT, Water, Anomaly, Weather, ITRI, Data collection, Fourth Industrial Revolution, Renewable energy, Itron

Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, signed a contract with PT.

Key Points: 
  • Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, signed a contract with PT.
  • MMID) to improve data collection and operational efficiencies in MM2100 Industrial Town , Indonesia’s fully integrated industrial estate.
  • MMID will deploy Temetra , Itron’s next-generation meter data collection and management solution, delivered via Itron channel partner PT.
  • Located in Bekasi West Java Province, about one hour from Jakarta, MM2100 Industrial Town continues to grow as an integrated and sustainable society.

Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Degenerative disease, Risk, Eosinophil, NASDAQ, T helper cell, Vaccination, Influenza, Trial of the century, Respiratory syncytial virus, Forward-looking statement, SEC, Viral load, Interferon, Incidence, MMID, Rhinovirus, Data analysis, Severe acute respiratory syndrome coronavirus 2, Immunity, TLR4, Technology, COVID-19, RT, GLOBE, RSV, EMA, Infection, AUC, CCR3, Allergic rhinitis, Immunization, SAN, FDA, Seroconversion, Disease, Revelation, Pharmaceutical industry, Vaccine

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, outlines details on the upcoming data analysis for Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99a for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans. Dosing and enrollment for this study were recently completed and primary endpoint analysis is expected early Q2 2022, followed by final data analysis in Q2 2022.

Key Points: 
  • Dosing and enrollment for this study were recently completed and primary endpoint analysis is expected early Q2 2022, followed by final data analysis in Q2 2022.
  • The Phase 2b, randomized, double-blind, placebo-controlled study was conducted in Belgium and enrolled healthy individuals 18 to 55 years of age.
  • Generally, the higher the amount of virus (viral load), the more infected, and by conjunction, the sicker a person may be.
  • The viral challenge study is the next necessary step in clinical development of REVTx-99a for the treatment of respiratory viral infections.

Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Tuesday, March 15, 2022
Viral load, SEC, Trial of the century, Influenza, Degenerative disease, Technology, GLOBE, Polyp, RSV, Immunity, Allergic rhinitis, Private Securities Litigation Reform Act, FDA, T helper cell, Risk, COVID-19, Infection, EMA, Eosinophil, Forward-looking statement, AUC, NASDAQ, TLR4, CCR3, Respiratory syncytial virus, Seroconversion, Incidence, Severe acute respiratory syndrome coronavirus 2, Interferon, Revelation, MMID, SAN, Rhinovirus, Vaccination, Disease, Vaccine, Pharmaceutical industry

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has completed enrollment and dosing in Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.
  • The Phase 2b, randomized, double-blind, placebo-controlled study was conducted in Belgium and enrolled healthy individuals 18 to 55 years of age.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity.

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Thursday, January 20, 2022
Vaccination, Forward-looking statement, Patient, Technology, Degenerative disease, SAN, Vaccine, Allergic rhinitis, Incidence, Private Securities Litigation Reform Act, EMA, SEC, COVID-19, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Influenza, Seroconversion, Safety, NASDAQ, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, AUC, Infection, Viral load, Immunity, MMID, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Polyp, Online shopping

The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.
  • With respiratory viral infections like influenza, COVID-19, and its emerging variants there is a huge need for new therapies, said James Rolke, Chief Executive Officer of Revelation.
  • Despite having vaccines, there remains an urgent need for multiple therapeutic approaches to help prevent and treat respiratory viral infections.
  • The Phase 2b, randomized, double-blind, placebo-controlled study will enroll up to 60 participants (four groups of 15 patients).

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

Retrieved on: 
Wednesday, December 1, 2021
Special, CCR3, Form, Vaccination, Prospectus, Immunity, Risk, GLOBE, Incidence, Infection, RSV, Influenza, Private Securities Litigation Reform Act, Degenerative disease, Eosinophil, Death, Research, Tripura Merger Agreement, File, T helper cell, Failure, TLR4, Interferon, Sale, Forward-looking statement, Absenteeism, Seroconversion, PETRA, NASDAQ, Business architecture, Mergers and acquisitions, FDA, Rhinovirus, Polyp, Allergic rhinitis, Securities Act of 1933, Safety, Technology, Acquisition, Severe acute respiratory syndrome coronavirus 2, SEC, Proxy, SAN, Business, Revelation, COVID-19, Nasdaq, EMA, Ownership, Name, CDC, MMID, AUC, Respiratory syncytial virus, Disease, Vaccine, Online shopping, Financial services

The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REXTx-99 for the treatment of respiratory viral infections.
  • The start of our viral challenge study is an important step in bringing a potential new therapy to bear on this problem.
  • The Phase 2b, randomized, double-blind, placebo-controlled study will enroll up to 60 participants.
  • The primary endpoint is to evaluate the efficacy of REVTx-99 in reducing influenza virus load in the upper airways during infection.